Header links
Intranet
Donate now
image/svg+xml Map
Contact us

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)

Contact
  • Protocol code: ENTR-601-44-201
  • EudraCT code: 2024-517584-23-00
  • Pathology: Duchenne muscular dystrophy
  • Pharmac: Hydrocortisone
  • Promoter: Entrada Theraputics, Inc.
  • Principal investigator:  Gómez Andrés, David
  • Research group:  Teràpies i Innovació en Neuropediatria i altres malalties rares pediàtriques.
  • Service: Neurologia pediàtrica
  • Phase: Fase I
  • Recruiting: Open
  • Status: Activo

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de tolerabilidad y aceptación de dos fórmulas magistrales de hidrocortisona oral para pediatría

Contact
  • Protocol code: HIDROGUM21
  • EudraCT code: 2021-001069-20
  • Pathology: Adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency).
  • Promoter: Hospital Universitario Vall Hebron
  • Principal investigator:  Parramon Teixido, Carlos Javier
  • Research group:  Recerca en farmacia bàsica, translacional i clínica
  • Service: Farmàcia
  • Phase: Fase IV
  • Recruiting: Open
  • Status: Activo

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Recombination Chimeric Monoclonal Antibody CH.14.18

Contact
  • Protocol code: SIOPENRNET002
  • EudraCT code: 2006-001489-17
  • Pathology: Neuroblastoma
  • Pharmac: Anticuerpo monoclonal recombinante antiGDch14.18.
  • Promoter: Dra. Victoria Castel (Hospital La Fe de Valencia)
  • Principal investigator:  Moreno Martín-Retortillo, Lucas
  • Research group:  Càncer i malalties hematològiques infantils
  • Service: Oncohematologia Pediàtrica
  • Phase: Fase III
  • Recruiting: Open
  • Status: Activo

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)

Contact
  • Protocol code: CSEG101A2301
  • EudraCT code: 2017-001746-10
  • Pathology: Sickle cell disease
  • Pharmac: Crizanlizumab
  • Promoter: Novartis Pharma AG
  • Principal investigator:  Beneitez Pastor, David
  • Research group:  VHIO (Grups bàsics i clínics)
  • Service: Hematologia
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Finalizado

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio en fase III, aleatorizado, abierto, con control activo, multicéntrico, para evaluar la eficacia y la seguridad de crovalimab frente a eculizumab en pacientes adultos y adolescentes con hemoglobinuria paroxística nocturna (HPN) actualmente tratada con inhibidores del complemento

Contact
  • Protocol code: BO42161
  • EudraCT code: 2020-000597-26
  • Pathology: Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Pharmac: CROVALIMAB
  • Promoter: F. Hoffmann-La Roche AG (Switzerland)
  • Principal investigator:  Beneitez Pastor, David
  • Research group:  VHIO (Grups bàsics i clínics)
  • Service: Hematologia
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Finalizado

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos con una extensión abierta para evaluar la eficacia y la seguridad de rilzabrutinib por vía oral (PRN1008) en adultos y adolescentes con trombocitopenia inmunitaria (TPI) persistente o crónica

Contact
  • Protocol code: PRN1008-018
  • EudraCT code: 2020-002063-60
  • Pathology: Immune Thrombocytopenia (ITP)
  • Pharmac: Rilzabrutinib (PRN1008)
  • Promoter: Principia Biopharma Inc. (United States)
  • Principal investigator:  Valcarcel Ferreiras, David
  • Research group:  VHIO (Grups bàsics i clínics)
  • Service: Hematologia
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Finalizado

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo multinacional, abierto, aleatorizado y controlado para investigar la eficacia y la seguridad de NNC0365-3769 (Mim8) en adultos y adolescentes con hemofilia A con o sin inhibidores

Contact
  • Protocol code: NN7769-4514
  • EudraCT code: 2020-001048-24
  • Pathology: Hemofilia A con inhibidores
  • Pharmac: NNC0365-3769 (Mim8)
  • Promoter: Novo Nordisk A/S
  • Principal investigator:  Benitez Hidalgo, Olga
  • Research group:  VHIO (Grups bàsics i clínics)
  • Service: Hematologia
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Cerrado

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio abierto para investigar la eficacia, la seguridad y la farmacocinética de la profilaxis con concizumab en niños menores de 12 años con hemofilia A o B con o sin inhibidores

Contact
  • Protocol code: NN7415-4616
  • EudraCT code: 2020-000504-11
  • Pathology: Haemophilia A or B with or without inhibitors
  • Pharmac: Concizumab
  • Promoter: Novo Nordisk A/S
  • Principal investigator:  Benitez Hidalgo, Olga
  • Research group:  VHIO (Grups bàsics i clínics)
  • Service: Hematologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Activo

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A phase 3b open-label, multicenter study evaluating physicalactivity and joint health in previously treated patients =12 years of age with severehaemophilia A treated with intravenous recombinant coagulation factor VIII FcvonWillebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocogalfa) for 24 months.

Contact
  • Protocol code: BIVV001-001
  • EudraCT code: 2022-500275-31-00
  • Pathology: Haemophilia A
  • Pharmac: Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001)
  • Promoter: Swedish Orphan Biovitrum AB (publ) (Sweden)
  • Principal investigator:  Benitez Hidalgo, Olga
  • Research group:  VHIO (Grups bàsics i clínics)
  • Service: Hematologia
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Finalizado

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de dosis escalonadas para evaluar la farmacocinética, eficacia y seguridad de apotransferrina en pacientes con atransferrinemia.

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Subscribe to